SDAI Limited Announces Strategic Supplier Agreement for Longevity Supplement Distribution
Key Highlights and Detailed Insights for Investors
1. Introduction: Expansion into Longevity Nutraceuticals Market
SDAI Limited has announced a significant update to its cooperation agreement with LiveBeyond Pte. Ltd., marking the entry into a new supplier agreement for the manufacturing and supply of Calcium Alpha-Ketoglutarate (AKG) supplements. This agreement is a strategic move that positions SDAI Healthcare, a subsidiary of the Group, to distribute these longevity-focused nutraceuticals across key Asian markets, including the People’s Republic of China (excluding Taiwan), Hong Kong, Macau, and Singapore, with potential for further territory expansion subject to mutual agreement.
2. Details of the Supplier
The Supplier is a biotechnology company based in the United States, specializing in the development of longevity and anti-aging nutraceuticals. Its flagship product is formulated to support healthy biological aging, targeting the growing demand for non-drug solutions to extend human health span. Notably, the Supplier is recognized as an approved supplier by LiveBeyond Pte. Ltd., the Consultant involved in the cooperation agreement.
3. Terms of the Supplier Agreement
- Effective Date: 17 June 2026
- Initial Term: Three years
- Renewal: Automatic renewal for an additional two years unless either party provides 90 days’ written notice of non-renewal or terminates the agreement per its terms
- Scope: Manufacture and supply of AKG supplements for distribution in agreed territories
4. Financial Impact and Uncertainties
The company has stated that the entry into the Supplier Agreement, alongside the activation of the Cooperation Agreement, is not expected to have a material impact on the Group’s net tangible assets and earnings per share for the financial year ending 31 December 2026 (FY2026). However, the financial impact may change as the sales uptake of the AKG product cannot be quantified at this time. Investors should note that revenue and profit contributions from this new venture remain uncertain and unquantified, introducing a degree of unpredictability to future financial performance.
5. Interests of Directors and Substantial Shareholders
No directors, substantial shareholders, or their respective associates have any direct or indirect interest in the Supplier Agreement, except through their shareholdings in SDAI Limited. This transparency reduces concerns about potential conflicts of interest.
6. Cautionary Statements and Trading Status
Investors are reminded that SDAI Limited shares have been suspended from trading on the Singapore Exchange since 12 July 2021. The company advises shareholders and potential investors to consult professional advisers if in doubt regarding this announcement or further developments.
Importantly, there is no assurance that the commercial objectives of the Supplier Agreement and related Cooperation Agreement will be fully realised. Investors should monitor future announcements closely, as material developments may affect the company’s prospects.
7. Potential Price-Sensitive Factors
- Entry into a new and rapidly growing longevity/anti-aging nutraceuticals market
- Potential for significant revenue uplift depending on product uptake, although currently unquantifiable
- Long-term contract with automatic renewal, providing stability in supply and potential expansion opportunities
- Share trading suspension remains in effect, impacting liquidity and immediate price reactions
Conclusion
This agreement marks a strategic shift for SDAI Limited into the health and wellness sector. While the immediate financial impact is not material and sales figures are uncertain, the long-term potential for growth in the anti-aging market could influence future valuation. Investors should stay alert for subsequent announcements as developments unfold.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own research and consult professional advisers before making investment decisions. The company’s shares are currently suspended, and there is no guarantee that the objectives of the agreements discussed will be achieved.
中文版本
1. 简介：进军长寿营养保健品市场
SDAI Limited宣布与LiveBeyond Pte. Ltd.的合作协议迎来重大更新，集团旗下SDAI Healthcare已签署新的供应商协议，将生产和供应钙α-酮戊二酸（AKG）补充剂。这一战略举措使SDAI Healthcare得以在包括中国大陆（不包括台湾）、香港、澳门和新加坡在内的主要亚洲市场分销这类长寿保健品，并有机会根据双方书面协议扩展至更多地区。
2. 供应商信息
供应商为美国的一家生物科技公司，专注于开发长寿、抗衰老的营养保健品，其旗舰产品旨在支持健康的生物老化，满足对非药物延长健康寿命的日益增长需求。值得注意的是，该供应商已被LiveBeyond Pte. Ltd.认可为合格供应商。
3. 协议主要条款
- 生效日期：2026年6月17日
- 初始期限：三年
- 续约：协议将自动续约两年，除非任何一方提前90天书面通知不续约或按照协议条款提前终止
- 范围：生产和供应AKG补充剂，分销至双方约定的地区
4. 财务影响和不确定性
公司表示，签署供应商协议及合作协议生效预计不会对集团2026财年（截至2026年12月31日）的净有形资产和每股收益产生实质性影响。然而，因AKG产品销售尚无法量化，财务影响存在一定的不确定性，投资者需注意未来业绩可能波动。
5. 董事及主要股东的利益
董事、主要股东及其关联人士除通过持有公司股份外，并无对供应商协议的直接或间接利益，确保利益透明，减小潜在利益冲突。
6. 风险提示及交易状态
投资者需注意，SDAI Limited股票自2021年7月12日起已在新加坡交易所暂停交易。公司建议股东及潜在投资者如有疑问，应咨询专业顾问。
尤其要注意，合作协议及供应商协议的商业目标能否全部实现尚无保证，投资者应密切关注后续公告及重大进展。
7. 可能影响股价的因素
- 进军快速增长的长寿/抗衰老营养保健品市场
- 产品销售情况如达预期，未来收入可能大幅提升，但目前无法量化
- 长期合同自动续约，供应稳定且有扩展机会
- 股票交易暂停，影响流动性及即时价格反应
结论
此协议标志着SDAI Limited战略转向健康与保健行业。虽然短期财务影响不大且销售数据不确定，但长寿市场的长期增长潜力值得关注。投资者应密切关注后续公告及相关进展。
免责声明
本文仅供参考，不构成投资建议。投资者应自行研究并咨询专业顾问后再做出投资决策。公司股票目前暂停交易，协议目标能否实现尚无保证。
